Ninlaro ixazomib: Preliminary Phase I/II data

Preliminary data from 9 evaluable patients with relapsed or refractory MM in an open-label, U.S. Phase I/II trial showed

Read the full 197 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE